Maravai continues genomics investment with Glen Research purchase

04-Jan-2018 - Last updated on 04-Jan-2018 at 15:59 GMT

(Image: Getty/SergeyNivens)

Specialty reagent provider Maravai LifeSciences has acquired Glen Research Corporation to provide more comprehensive solutions to its customers, says VP.

Sterling, VA-based Glen Research provides a range of reagents used in the synthesis of DNA and RNA.

Maravai LifeSciences is a portfolio company of GTCR, a private equity firm, and provides specialty reagents to researchers and biotherapeutics manufacturers globally. GTCR’s portfolio companies also includes AMRI and Sterigenics International, among others.

David Weber, vice president and chief commercial officer of Maravai, told us the Glen Research acquisition continues the company’s investment in genomics, which began with its acquisition of TriLink BioTechnologies in 2016.

In addition to TriLink, and now Glen Research, Maravai also owns Vector Laboratories and Cygnus Technologies.

“Furthermore and core to all of our businesses is our focus on quality for which Glen Research has an outstanding reputation,” added Weber.

“In addition, as TriLink BioTechnologies and Glen Research offer products, services, and expertise in the area of oligonucleotide synthesis, we can therefore provide more comprehensive solutions to our customers.”

As per integration, Weber said systems, processes, and policies will be integrated “quite quickly.”

“We will also do some short-term integration of commercial activities,” he explained. “However the Glen Research team will remain in place in our Sterling, VA facility.”